The FDA approved talazoparib (Talzenna, Pfizer) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Efficacy was evaluated in TALAPRO-2, a randomized, double-blind, placebo-controlled, multi-cohort trial enrolling 399 patients with HRR gene-mutated mCRPC. Patients were randomized in a 1:1 fashion to receive enzalutamide 160 mg daily plus either talazoparib 0.5 mg or placebo daily. Patients were required to have a prior
JUNE 26, 2023